Insulin Icodec Bests Degludec; FDA's T2D Device Guidance; Farxiga Cuts HF Risks | MedPage Today
Insulin "Icodec" Could Be a Diabetes Breakthrough with a Half Life of Over 8 Days - The Diabetes Site News
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk's once-weekly insulin hits goals in phase 3 trials
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
The promising future of insulin therapy in diabetes mellitus | American Journal of Physiology-Endocrinology and Metabolism
Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes
Novo afslutter sidste af seks succesfulde studier med ugentlig insulin - Dagens Medicin
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk's insulin icodec beats other insulin therapies in diabetes study | S&P Global Market Intelligence
Novo Nordisk to file for regulatory approval of once-weekly insulin icodec next year
Once-Weekly Insulin Icodec Promising for Type 2 Diabetes - Consumer Health News | HealthDay
Novo Nordisk once-weekly insulin icodec beats Tresiba, matches Sanofi's Lantus in trials | Seeking Alpha
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
